Single-dose euglycemic clamp study in two cohorts to compare exposure of SAR341402 (insulin aspart) Mix 70/30 to US- and EU-Approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes

COMMENTED

Type 1 DiabetesPediatric Diabetes

Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial

Diabetes Care.

Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao PV, Deenadayalan S, Ekelund M, Larsen SF, Danne T

doi: 10.2337/dc19-0009.

COMMENTED

Type 1 Diabetes

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study

Diabetes Care.

Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM, DCCT/EDIC Research Group

doi: 10.2337/dc18-1574.

Diabetes - GeneralType 1 Diabetes

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1)

Diabetes Care.

Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM

doi: 10.2337/dc16-1771.

COMMENTED

Type 2 Diabetes

Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes

Diabet Med.

Bowering K, Harvey J, Kolaczynski JW, Snyder JW, Bode BW

doi: 10.1111/dme.13866.

COMMENTED

Type 2 Diabetes

A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy

Diabetes Care.

Grubb AL, McDonald TJ, Rutters F, Donnelly LA, Hattersley AT, Oram RA, Palmer CNA, van der Heijden AA, Carr F, Elders PJM, Weedon MN, Slieker RC, 't Hart LM, Pearson ER, Shields BM, Jones AG

doi: 10.2337/dc18-0431.

Type 1 DiabetesGlycemic Control

Hypoglycaemia is reduced with use of inhaled Technosphere^® Insulin relative to insulin aspart in type 1 diabetes mellitus

Diabet Med.

Seaquist ER, Blonde L, McGill JB, Heller SR, Kendall DM, Bumpass JB, Pompilio FM, Grant ML

doi: 10.1111/dme.14202.

RECOMMENDED

Type 1 DiabetesType 2 DiabetesPediatric Diabetes

Disordered Eating Behaviors in Youth and Young Adults With Type 1 or Type 2 Diabetes Receiving Insulin Therapy: The SEARCH for Diabetes in Youth Study

Diabetes Care.

Nip ASY, Reboussin BA, Dabelea D, Bellatorre A, Mayer-Davis EJ, Kahkoska AR, Lawrence JM, Peterson CM, Dolan L, Pihoker C, SEARCH for Diabetes in Youth Study Group

doi: 10.2337/dc18-2420.

COMMENTED

Type 2 DiabetesGlycemic Control

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9)

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.2337/dc19-2232.

COMMENTED

Type 1 Diabetes

Glucose control using fast-acting insulin aspart in a real-world setting: a 1-year two-center study in people with type 1 diabetes using continuous glucose monitoring

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Obes Metab

Billion L, Charleer S, Verbraeken L, Sterckx M, Vangelabbeek K, De Block N, Janssen C, Van Dessel K, Dirinck E, Peiffer F, Bolsens N, Mathieu C, Gillard P, De Block C

doi: 10.1111/dom.14527

Related content

Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1)

Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes

A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy

Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus

Disordered Eating Behaviors in Youth and Young Adults With Type 1 or Type 2 Diabetes Receiving Insulin Therapy: The SEARCH for Diabetes in Youth Study

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9)

Glucose control using fast-acting insulin aspart in a real-world setting: a 1-year two-center study in people with type 1 diabetes using continuous glucose monitoring

Hypoglycaemia is reduced with use of inhaled Technosphere^® Insulin relative to insulin aspart in type 1 diabetes mellitus